Kyle Munz

Brendon Yee, PhD, professor and respiratory and sleep physician, Woolcock Institute of Medical Research, discusses the success of ALKS 2680, an investigational oral selective orexin 2 receptor agonist.

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options for patients with idiopathic pulmonary fibrosis (IPF).

Researchers evaluated the lesser-known impact of telehealth treatments, including brief cognitive behavioral therapy (BCBT), to address the needs of individuals at risk of or recovering from suicidal ideation.

Rebekah Walker, PhD, a first-time participant from the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, shares the offerings and opportunities at the 2024 American Heart Association (AHA) meeting that excited her and her team.

A decision from the American Board of Medical Specialties will be made about a new cardiovascular board by this upcoming February.

The connection between brain, mental, and cardiovascular health needs considerable more attention, argues Maureen Hood, PhD, RN, Uniformed Services University.

Key Takeaways The ABCVM aims to address the specialization of cardiovascular services and ensure continuous competency in the field.

The FINEARTS-HF trial offered novel clinical insights as one of the few cardiovascular trials to feature such a great proportion of female participants.

Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.

The implementation of a risk evaluation mitigation strategy (REMS) program to monitor patients on mavacamten further supports its real-world use, according to Milind Desai, MD, Cleveland Clinic.